Apricus Biosciences

About:

Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that has an approved product, Vitaros®, for the treatment of ED.

Twitter/X: ApricusBio

Description:

Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that has an approved product, Vitaros®, for the treatment of ED. Vitaros® is approved in Europe and Canada and will be commercialized by Apricus’ marketing partners, which include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), and Bracco SpA. Femprox®, the Company’s product candidate for the treatment of FSAID, has successfully completed a nearly 400-subject proof-of-concept study.

Total Funding Amount:

$12.3M

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

San Diego, California, United States

Founded Date:

1987-01-01

Founders:

Number of Employees:

51-100

Last Funding Date:

2016-03-04

IPO Status:

Public

Industries: